Nanobiotix Sa ADR (NBTX)
NASDAQ:NBTX
Want to see NBTX full AI Analyst Report?
NBTX Stock Chart & Stats
$33.79
-$0.03(-1.02%)
At close: 4:00 PM EST
$33.79
-$0.03(-1.02%)
Day’s Range― - ―
52-Week Range$4.31 - $57.14
Previous CloseN/A
Volume23.08K
Average Volume (3M)77.44K
Market Cap
$1.76B
Enterprise Value$1.60B
Total Cash (Recent Filing)$52.75M
Total Debt (Recent Filing)$95.32M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Sep 30, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding50,619,583
10 Day Avg. Volume68,362
30 Day Avg. Volume77,436
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)-11.14
Price to Sales (P/S)31.74
P/FCF Ratio-27.70
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue54.00
Enterprise Value/Gross Profit54.00
Enterprise Value/Ebitda-132.64
Forecast
1Y Price Target
$34.33Price Target Upside1.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$40.51M
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayA substantial follow-on offering materially strengthened liquidity and management states combined proceeds and cash support operations into 2029. This durable funding reduces near-term refinancing pressure, enables multi-year execution of late‑stage readouts and platform investments, and preserves optionality for partnerships and milestones.
Strategic Partnership With J&JTransferring pivotal Phase III responsibilities to Johnson & Johnson materially lowers Nanobiotix’s direct funding burden while providing access to J&J’s development, regulatory and commercialization infrastructure. This partnership accelerates global scale potential and aligns future milestone/royalty upside with a major pharma partner.
Platform & IP Progress (Curadigm)Progress on the Nanoprimer/Curadigm platform — new patents, GMP/CMC work, multiple MTAs and supportive preclinical data — builds a durable technology moat and multiple commercialization pathways. Platform IP and partner engagement increase licensing and collaboration optionality beyond the lead oncology asset.
Bears Say
Balance‑sheet LeveragePersistent negative equity and elevated debt levels indicate structural capitalization weakness, limiting financial flexibility. High leverage relative to assets increases refinancing and covenant risk, may raise borrowing costs, and can force dilutive capital raises if clinical or milestone inflows disappoint.
Persistent Cash BurnConsistently negative operating and free cash flow show the business remains financing‑dependent. Even with recent raises, ongoing burn to support clinical programs and platform scale means the company will likely need future capital or milestone receipts, which can impose timing risk and potential dilution.
Dependence On J&J For Pivotal PathRelying on Johnson & Johnson to manage pivotal trials and regulatory strategy reduces Nanobiotix’s control over timelines, endpoints and filing decisions. This governance asymmetry can delay commercialization, concentrate execution risk externally, and limit the company's ability to unilaterally capture upside from positive clinical outcomes.
NBTX FAQ
What was Nanobiotix Sa ADR’s price range in the past 12 months?
Nanobiotix Sa ADR lowest stock price was $4.31 and its highest was $57.14 in the past 12 months.
What is Nanobiotix Sa ADR’s market cap?
Nanobiotix Sa ADR’s market cap is $1.76B.
When is Nanobiotix Sa ADR’s upcoming earnings report date?
Nanobiotix Sa ADR’s upcoming earnings report date is Sep 30, 2026 which is in 103 days.
How were Nanobiotix Sa ADR’s earnings last quarter?
Currently, no data Available
Is Nanobiotix Sa ADR overvalued?
According to Wall Street analysts Nanobiotix Sa ADR’s price is currently Undervalued.
Does Nanobiotix Sa ADR pay dividends?
Nanobiotix Sa ADR does not currently pay dividends.
What is Nanobiotix Sa ADR’s EPS estimate?
Nanobiotix Sa ADR’s EPS estimate is -0.29.
How many shares outstanding does Nanobiotix Sa ADR have?
Nanobiotix Sa ADR has 50,619,583 shares outstanding.
What happened to Nanobiotix Sa ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix Sa ADR?
Currently, no hedge funds are holding shares in NBTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nanobiotix Stock Smart Score
Company Description
Nanobiotix Sa ADR
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
NBTX Company Deck
NBTX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Positive overall. The company reported meaningful financial and operational improvements driven by (a) removal of large development obligations via the Janssen amendment, (b) nondilutive royalty financing that materially strengthens near-term liquidity, and (c) clinical progress across multiple programs including encouraging early CONVERGE lead-in data and continued Curadigm platform advancement (patents, MTAs, CMC/GMP start). Key risks remain: the FY2025 revenue uplift is largely a one‑time accounting effect, clinical readouts (notably CONVERGE and the Phase III head & neck study) are controlled by J&J and many pivotal data points are not expected until 2027, and the stated runway depends on receipt of remaining financing and potential milestone receipts. On balance, the positives (stronger cash runway, lower burn, decreased net loss, strategic financing, multiple clinical catalysts and platform progress) outweigh the listed risks and uncertainties.View all NBTX earnings summariesNBTX Stock 12 Month Forecast
Average Price Target
$34.33
▲(1.61% Upside)
Technical Analysis
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Septerna, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
11.11% Other Institutional Investors
88.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---